BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 15808774)

  • 1. The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry.
    Ong AT; Serruys PW; Aoki J; Hoye A; van Mieghem CA; Rodriguez-Granillo GA; Valgimigli M; Sonnenschein K; Regar E; van der Ent M; de Jaegere PP; McFadden EP; Sianos G; van der Giessen WJ; de Feyter PJ; van Domburg RT
    J Am Coll Cardiol; 2005 Apr; 45(7):1135-41. PubMed ID: 15808774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry.
    Onuma Y; Kukreja N; Piazza N; Eindhoven J; Girasis C; Schenkeveld L; van Domburg R; Serruys PW;
    J Am Coll Cardiol; 2009 Jul; 54(3):269-76. PubMed ID: 19589442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry.
    Lemos PA; Serruys PW; van Domburg RT; Saia F; Arampatzis CA; Hoye A; Degertekin M; Tanabe K; Daemen J; Liu TK; McFadden E; Sianos G; Hofma SH; Smits PC; van der Giessen WJ; de Feyter PJ
    Circulation; 2004 Jan; 109(2):190-5. PubMed ID: 14691037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative clinical outcomes of paclitaxel- and sirolimus-eluting stents: results from a large prospective multicenter registry--STENT Group.
    Simonton CA; Brodie B; Cheek B; Krainin F; Metzger C; Hermiller J; Juk S; Duffy P; Humphrey A; Nussbaum M; Laurent S;
    J Am Coll Cardiol; 2007 Sep; 50(13):1214-22. PubMed ID: 17888837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sirolimus-eluting stents remain superior to bare-metal stents at two years: medium-term results from the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry.
    Ong AT; van Domburg RT; Aoki J; Sonnenschein K; Lemos PA; Serruys PW
    J Am Coll Cardiol; 2006 Apr; 47(7):1356-60. PubMed ID: 16580521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Four-year clinical outcome of sirolimus- and paclitaxel-eluting stents compared to bare-metal stents for the percutaneous treatment of stable coronary artery disease.
    Simsek C; Onuma Y; Magro M; de Boer S; Battes L; van Domburg RT; Boersma E; Serruys PW;
    Catheter Cardiovasc Interv; 2010 Jul; 76(1):41-9. PubMed ID: 20310019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three-year outcomes following sirolimus- versus paclitaxel-eluting stent implantation in an unselected population with coronary artery disease (from the REWARDS Registry).
    Hanna NN; Gaglia MA; Torguson R; Ben-Dor I; Gonzalez MA; Collins SD; Syed AI; Maluenda G; Kaneshige K; Xue Z; Satler LF; Kent KM; Suddath WO; Pichard AD; Waksman R
    Am J Cardiol; 2010 Aug; 106(4):504-10. PubMed ID: 20691308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of six-year clinical outcome of sirolimus- and paclitaxel-eluting stents to bare-metal stents in patients with ST-segment elevation myocardial infarction: an analysis of the RESEARCH (rapamycin-eluting stent evaluated at Rotterdam cardiology hospital) and T-SEARCH (taxus stent evaluated at Rotterdam cardiology hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta S; Daemen J; Gaspersz M; van Geuns RJ; van der Giessen W; van Domburg R; Serruys P
    J Invasive Cardiol; 2011 Aug; 23(8):336-41. PubMed ID: 21828397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term clinical outcomes of sirolimus- versus paclitaxel-eluting stents for patients with unprotected left main coronary artery disease: analysis of the MAIN-COMPARE (revascularization for unprotected left main coronary artery stenosis: comparison of percutaneous coronary angioplasty versus surgical revascularization) registry.
    Lee JY; Park DW; Yun SC; Lee SW; Kim YH; Lee CW; Hong MK; Park SW; Park SJ
    J Am Coll Cardiol; 2009 Aug; 54(9):853-9. PubMed ID: 19695467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome in the real-world of coronary high-risk intervention with drug-eluting stents (ORCHID) -- a single-center study comparing Cypher sirolimus-eluting with Taxus paclitaxel-eluting stents.
    Kumar S; Suresh V; Prendergast BD; Brooks NH; Wicks P; Levy RD; Ray SG; Bennett DH; Lee HS
    Catheter Cardiovasc Interv; 2006 Nov; 68(5):663-8. PubMed ID: 17034063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-year outcome of patients treated with sirolimus- versus paclitaxel-eluting stents in an unselected population with coronary artery disease (from the REWARDS Registry).
    Roy P; Bonello L; de Labriolle A; Okabe T; Pinto Slottow TL; Steinberg DH; Torguson R; Smith K; Xue Z; Satler LF; Kent KM; Suddath WO; Pichard AD; Waksman R
    Am J Cardiol; 2008 Aug; 102(3):292-7. PubMed ID: 18638589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-year clinical outcome after coronary stenting of small vessels using 2.25-mm sirolimus- and paclitaxel-eluting stents: insight into the RESEARCH and T-SEARCH registries.
    Tanimoto S; Daemen J; Tsuchida K; García-García HM; de Jaegere P; van Domburg RT; Serruys PW
    Catheter Cardiovasc Interv; 2007 Jan; 69(1):94-103. PubMed ID: 17139687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries).
    Daemen J; Tanimoto S; García-García HM; Kukreja N; van de Sande M; Sianos G; de Jaegere PP; van Domburg RT; Serruys PW
    Am J Cardiol; 2007 Apr; 99(8):1027-32. PubMed ID: 17437722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease.
    Schömig A; Dibra A; Windecker S; Mehilli J; Suárez de Lezo J; Kaiser C; Park SJ; Goy JJ; Lee JH; Di Lorenzo E; Wu J; Jüni P; Pfisterer ME; Meier B; Kastrati A
    J Am Coll Cardiol; 2007 Oct; 50(14):1373-80. PubMed ID: 17903638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
    Mehilli J; Kastrati A; Byrne RA; Bruskina O; Iijima R; Schulz S; Pache J; Seyfarth M; Massberg S; Laugwitz KL; Dirschinger J; Schömig A;
    J Am Coll Cardiol; 2009 May; 53(19):1760-8. PubMed ID: 19422982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of the unrestricted use of everolimus-eluting stents compared to sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients: the Bern-Rotterdam diabetes cohort study.
    Simsek C; Räber L; Magro M; Boersma E; Onuma Y; Stefanini GG; Zanchin T; Kalesan B; Wenaweser P; Jüni P; van Geuns RJ; van Domburg RT; Windecker S; Serruys PW
    Int J Cardiol; 2013 Dec; 170(1):36-42. PubMed ID: 24196314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of 2-year clinical outcomes with sirolimus and paclitaxel-eluting stents for patients with diabetes: results of the Registro Regionale AngiopLastiche Emilia-Romagna Registry.
    Balducelli M; Ortolani P; Marzaroli P; Piovaccari G; Menozzi A; Manari A; Sangiorgio P; Tarantino F; Rossi R; Maresta A; Tondi S; Passerini F; Guastaroba P; Grilli R; Marzocchi A
    Catheter Cardiovasc Interv; 2010 Feb; 75(3):327-34. PubMed ID: 19937776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus-eluting versus paclitaxel-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: a combined RESEARCH and T-SEARCH long-term analysis.
    Valgimigli M; Malagutti P; Aoki J; Garcia-Garcia HM; Rodriguez Granillo GA; van Mieghem CA; Ligthart JM; Ong AT; Sianos G; Regar E; Van Domburg RT; De Feyter P; de Jaegere P; Serruys PW
    J Am Coll Cardiol; 2006 Feb; 47(3):507-14. PubMed ID: 16458128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.